Literature DB >> 2403580

Regulation of the genes for heme pathway enzymes in erythroid and in non-erythroid cells.

S Sassa1.   

Abstract

There are eight enzymes in the heme biosynthetic pathway and three enzymes in the heme catabolic pathway. Enzymatic defects in heme biosynthesis lead to clinical conditions termed porphyrias. cDNAs for five of the eight enzymes in the heme biosynthetic pathway and two of the three enzymes in the heme catabolic pathway have been cloned and characterized in mammalian cells. At least two enzymes exist as isozymes between erythroid and non-erythroid tissues. One is delta-aminolevulinic acid synthase (ALAS), and the erythroid and hepatic isozymes are coded by two separate genes. The other is porphobilinogen deaminase (PBGD), and both the erythroid and the non-erythroid PBGD mRNA are transcribed from a single PBGD gene by alternate transcription and splicing. There is also a significant tissue-specific control of expression of the uroporphyrinogen decarboxylase gene which is expressed as a unique mRNA in all tissues.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403580     DOI: 10.1002/stem.5530080104

Source DB:  PubMed          Journal:  Int J Cell Cloning        ISSN: 0737-1454


  6 in total

Review 1.  [Hepatic porphyrias and alcohol].

Authors:  M O Doss; A Kühnel; U Gross; I Sieg
Journal:  Med Klin (Munich)       Date:  1999-06-15

2.  Nuclear distribution of porphobilinogen deaminase (PBGD) in glioma cells: a regulatory role in cancer transformation?

Authors:  L Greenbaum; Y Gozlan; D Schwartz; D J Katcoff; Z Malik
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

3.  Continuous de novo biosynthesis of haem and its rapid turnover to bilirubin are necessary for cytoprotection against cell damage.

Authors:  Taka-aki Takeda; Anfeng Mu; Tran Tien Tai; Sakihito Kitajima; Shigeru Taketani
Journal:  Sci Rep       Date:  2015-05-20       Impact factor: 4.379

4.  Haem Biosynthesis and Antioxidant Enzymes in Circulating Cells of Acute Intermittent Porphyria Patients.

Authors:  Miguel D Ferrer; Antonia Mestre-Alfaro; Magdalena Martínez-Tomé; Lucrecia Carrera-Quintanar; Xavier Capó; Antonia M Jiménez-Monreal; Luis García-Diz; Enrique Roche; María A Murcia; Josep A Tur; Antoni Pons
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

5.  Tips for erythropoiesis-stimulating agent treatment of renal anemia.

Authors:  Naohisa Tomosugi; Yoshitaka Koshino
Journal:  Clin Exp Nephrol       Date:  2019-10-16       Impact factor: 2.801

6.  Differentiation-dependent photodynamic therapy regulated by porphobilinogen deaminase in B16 melanoma.

Authors:  D Ickowicz Schwartz; Y Gozlan; L Greenbaum; T Babushkina; D J Katcoff; Z Malik
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.